That-Guy said:
i cant remember who posted it but Winstrol (winny) is ment to help fight gyno that is formed from deca...
I was never much interested in winstrol, but supposedly it helping stop progesterone effects are false.
Dont recall where this came from:
-
DOSAGE AND ADMINISTRATION
The recommended dosage of DOSTINEX Tablets for initiation of therapy is 0.25 mg twice a week. Dosage may be increased by 0.25 mg twice weekly up to a dosage of 1 mg twice a week according to the patient's serum prolactin level.
Dosage increases should not occur more rapidly than every 4 weeks, so that the physician can assess the patient's response to each dosage level. If the patient does not respond adequately, and no additional benefit is observed with higher doses, the lowest dose that achieved maximal response should be used and other therapeutic approaches considered.
After a normal serum prolactin level has been maintained for 6 months, DOSTINEX may be discontinued, with periodic monitoring of the serum prolactin level to determine whether or when treatment with DOSTINEX should be reinstituted. The durability of efficacy beyond 24 months of therapy with DOSTINEX has not been established.
In the 8-week, double-blind period of the comparative trial with bromocriptine, DOSTINEX (at a dose of 0.5 mg twice weekly) was discontinued because of an adverse event in 4 of 221 patients (2%) while bromocriptine (at a dose of 2.5 mg two times a day) was discontinued in 14 of 231 patients (6%). The most common reasons for discontinuation from DOSTINEX were headache, nausea and vomiting (3, 2 and 2 patients respectively); the most common reasons for discontinuation from bromocriptine were nausea, vomiting, headache, and dizziness or vertigo (10, 3, 3, and 3 patients respectively). The incidence of the most common adverse events during the double-blind portion of the comparative trial with bromocriptine is presented in the following table.
Incidence of Reported Adverse Events During
the 8-week, Double-Blind Period of
the Comparative Trial With Bromocriptine Adverse Event * Cabergoline
(n=221) Placebo
(n=231)
Number (percent)
Gastrointestinal
Nausea 63 (29) 100 (43)
Constipation 15 (7) 21 (9)
Abdominal pain 12 (5) 19 (8)
Dyspepsia 11 (5) 16 (7)
Vomiting 9 (4) 16 (7)
Dry mouth 5 (2) 2 (1)
Diarrhea 4 (2) 7 (3)
Flatulence 4 (2) 3 (1)
Throat irritation 2 (1) 0
Toothache 2 (1) 0
Central and Peripheral Nervous System
Headache 58 (26) 62 (27)
Dizziness 38 (17) 42 (18)
Vertigo 9 (4) 10 (4)
Paresthesia 5 (2) 6 (3)
Body As a Whole
Asthenia 13 (6) 15 (6)
Fatigue 10 (5) 18 (8)
Syncope 3 (1) 3 (1)
Influenza-like symptoms 2 (1) 0
Malaise 2 (1) 0
Periorbital edema 2 (1) 2 (1)
Peripheral edema 2 (1) 1
Psychiatric
Depression 7 (3) 5 (2)
Somnolence 5 (2) 5 (2)
Anorexia 3 (1) 3 (1)
Anxiety 3 (1) 3 (1)
Insomnia 3 (1) 2 (1)
Impaired concentration 2 (1) 1
Nervousness 2 (1) 5 (2)
Cardiovascular
Hot flashes 6 (3) 3 (1)
Hypotension 3 (1) 4 (2)
Dependent edema 2 (1) 1
Palpitation 2 (1) 5 (2)
Reproductive--Female
Breast pain 5 (2) 8 (3)
Dysmenorrhea 2 (1) 1
Skin and Appendages
Acne 3 (1) 0
Pruritus 2 (1) 1
Musculoskeletal
Pain 4 (2) 6 (3)
Arthralgia 2 (1) 0
Respiratory
Rhinitis 2 (1) 9 (4)
Vision
Abnormal vision 2 (1) 2 (1)
*Reported at >/=1% for cabergoline